Preprint Review Version 1 Preserved in Portico This version is not peer-reviewed

The Development of Immunotherapy for the Treatment of Recurrent Glioblastoma

Xudong Liu
,
Wufei Dai
,
Zihui Zhao
,
Kuo Liao
ORCID logo ,
Qi Sun
,
Dongjiang Chen
ORCID logo ,
Xinglin Pan
,
Lishuang Feng
,
Ying Ding
,
Shiyou Wei
*
Version 1 : Received: 25 July 2023 / Approved: 26 July 2023 / Online: 27 July 2023 (09:30:30 CEST)

A peer-reviewed article of this Preprint also exists.

Liu, X.; Zhao, Z.; Dai, W.; Liao, K.; Sun, Q.; Chen, D.; Pan, X.; Feng, L.; Ding, Y.; Wei, S. The Development of Immunotherapy for the Treatment of Recurrent Glioblastoma. Cancers 2023, 15, 4308. Liu, X.; Zhao, Z.; Dai, W.; Liao, K.; Sun, Q.; Chen, D.; Pan, X.; Feng, L.; Ding, Y.; Wei, S. The Development of Immunotherapy for the Treatment of Recurrent Glioblastoma. Cancers 2023, 15, 4308.

Abstract

ABSTRACT: Recurrent glioblastoma (rGBM) is a highly aggressive form of brain cancer that poses a significant challenge for treatment in neurooncology, and the survival status of patients after relapse usually means rapid deterioration, and also the leading cause of death among patients. In recent years, immunotherapy has emerged as a promising strategy for the treatment of recurrent glioblastoma by stimulate the body's immune system to recognize and attack cancer cells , which could be used as a in combination with other treatments such as surgery, radiation, and chemotherapy to improve outcomes for patients with recurrent glioblastoma, This therapy combines several key methods such as the use of monoclonal antibodies, chimeric antigen receptor T cell (CAR-T) therapy, checkpoint inhibitors, oncolytic viral therapy cancer vaccines, and combination strategies. In this review, we mainly document the latest immunotherapies for the treatment of glioblastoma and focus on the rGBM especially.

Keywords

Keywords： recurrent glioblastoma; immunotherapy; CAR-T therapy; immune checkpoint inhibitor; cancer vaccine; oncolytic viral therapy

Subject

Biology and Life Sciences, Biology and Biotechnology

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Download PDF

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Get PDF Cite Share 0
Bookmark BibSonomy Mendeley Reddit Delicious
×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.